Contact Us

Our Purpose

In 2022, the FDA Modernization Act took effect, and among its goals were to modernize the methods by which drugs are discovered, developed, and tested for safety and efficacy. The emergence of advanced, large-scale in vitro and in silico testing methods has ushered in a new era of drug development. With the encouragement of regulatory advisors who had seen our technology’s predictions and verifications over several years of work, we incorporated Phase Advance in order to bring our new approach methologies to the process of finding, vetting, and developing impactful drug candidates.

This legislation ... allows preclinical studies to adopt methods that may more accurately predict human responses based on the latest scientific advances rather than being solely dependent on increasingly outdated animal testing.

Zushin PH, Mukherjee S, Wu JC. FDA Modernization Act 2.0: Transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches. Journal of Clinical Investigation.

Our Mission

Reduce the cost of new medicines for all humanity using mathematics, artificial intelligence, and human biology to accurately predict cure rates 14 years in the future.

 

Our Vision

Accelerate humanity‘s future evolution beyond the species tipping point with non-linear mathematics, predictive AI, knowledge of human body function, and innovative medicines.

Our Values

Predicting the therapeutic future

Audacious

Continual innovation

A person is a person because of other people

Coding the future

Diversity and mathematics are the defining strength of humans and health

Our Team

Our leadership team brings together tremendous expertise from medicine, research, pharma development, mathematical modeling, AI, and startup growth.

Dr. Tawanda Gumbo

Cofounder & CEO

Tawanda Gumbo, MD, is ranked in the top 1% of scientists (not just life sciences) in terms of citations in the world based on the Stanford University 2% Global Scientists Citation Rankings. His lifelong approach has been application of advanced non-linear mathematical sciences and AI to drug development, starting 30 years ago. His contributions to science are in about 17 areas , including drug discovery, development of several new treatment rgeimens, pathogen discovery, systems pharmacology, mathematics, new disease descriptions, and several wet lab disease models. He has earned numerous awards for innovation based on these approaches, including the NIH Director’s New Innovator Award, serving on WHO taskforces, and D CEO Excellence in Healthcare. He has published about 220 peer reviewed scientifc publications and include the world’s first strictly virtual clinical trial.

At Phase Advance he has leveraged the 30+ years in medical research, clinical practice, multiple clinical trials design and execution, and development of systems of systems wet lab based approches to drug development. The system of systems drug development approach led to his founding of Praedicare Inc in 2019. Training started at the University of Zimbabwe, through Case Western Reserve University and finally at the Cleveland Clinic, in Cleveland, Ohio. He has led research programs at University of Texas Southwestern Medical Center and Baylor University Medical Center in Dallas, Texas. He writes two book chapters in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th & 13th Editions, effectinately called the the "bible of pharmacology".

Dr. Gesham Magombedze

Cofounder and Chief AI & Math Modeling Officer

Dr. Magombedze has 20+ years expertise in mathematical, computational, and bioinformatics, with over 15 years developing techniques to model human disease processes and immune responses. He is a global leader in translational models that predict the outcomes of newly discovered pharmaceuticals.

He spent four years at Gilead, building the company’s mathematical Modeling department.

Magombedze has elucidated complex, nonlinear disease progression for pharma development and validation. His work has led the industry in advanced pharmacokinetics and pharmacodynamics understanding, and insights into the effects of resistance on microbial fitness.

Rachael Sparks

Cofounder & Chief Marketing Officer

Rachael Sparks holds a degree in Microbiology from Texas A&M University. After several years as a transplant specialist, she joined the startup environment to lead marketing, provide technical direction, and serve as corporate spokesperson at Xenex Disinfection Services. Rachael helped to grow Xenex from the first ever pulsed-xenon UV disinfection robot to worldwide healthcare market leader, now the only UV disinfecting system with de novo FDA device clearance. She then served as VP of Marketing for the US branch of Italian pharmaceutical leader Angelina Pharma, and later as VP of Marketing for award-winning healthcare startup Kinnos. She is a consultant and advisor to several startups in the med tech and biopharma space. In 2024 she cofounded Phase Advance to modernize drug development with groundbreaking models of disease progression.

Join the future with us.

Schedule a call to learn how Phase Advance AI can advance your project.

Contact Us

© 2025 All Rights Reserved.